Platinum-based chemotherapy clinical trials
7 indexed studies · 3 currently recruiting
- Active not recruitingPHASE3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
This study looks at a new drug, patritumab deruxtecan, for a type of lung cancer that has stopped responding to standard treatments. It compares this new drug with traditional chemotherapy to see if it works better and is safer for patients.
For: Nonsquamous Non-small Cell Lung Cancer · EGFR L858R · EGFR Exon 19 DeletionUnited States · Australia · Austria - Active not recruitingPHASE1
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
This study is testing a new drug, BAY2965501, for advanced cancers like skin, kidney, stomach, and lung cancer. It aims to find a safe dose, how it affects the body, and if it helps shrink tumors. The drug works by boosting the body's own immune cells to fight cancer.
For: Advanced Solid TumorsUnited States · Belgium · China - RecruitingPHASE2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat early-stage lung cancer. We want to see if adding an extra treatment to cemiplimab and chemotherapy works better before surgery. It's for adults whose lung cancer can be removed by an operation.
For: Non-Small Cell Lung CancerUnited States · Brazil · France - Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
This study looks at how a medicine called cemiplimab (Libtayo®) works for adults with advanced non-small cell lung cancer in everyday healthcare. Researchers want to understand its benefits and safety in real-world use.
For: Non-small Cell Lung CancerAustria · France · Germany - Active not recruitingPHASE3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
This study compares a new drug, furmonertinib, at two different strengths, with standard chemotherapy for patients in the UK who have advanced non-small cell lung cancer with a specific genetic change called an EGFR exon 20 insertion mutation. It aims to see which treatment is more effective and safe as a first treatment.
For: Metastatic Non-Small Cell Lung Cancer · Advanced Non-Small Cell Lung Cancer · EGFR Exon 20 MutationsUnited States · Australia · Brazil - RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
For: Metastatic Non-small Cell Lung CancerUnited States · Austria · Belgium - Active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
For: Ovarian Cancer · Fallopian Tube Cancer · Neoadjuvant TreatmentCanada · New Zealand · Spain